A detailed history of Legal & General Group PLC transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 3,912 shares of PBYI stock, worth $10,092. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,912
Holding current value
$10,092
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.92 - $5.83 $11,423 - $22,806
3,912 New
3,912 $12,000
Q2 2022

Aug 22, 2022

SELL
$1.64 - $3.3 $5,828 - $11,728
-3,554 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$2.85 - $6.58 $24,105 - $55,653
-8,458 Reduced 70.41%
3,554 $11,000
Q3 2021

Nov 15, 2021

BUY
$6.63 - $9.39 $39,561 - $56,030
5,967 Added 98.71%
12,012 $84,000
Q1 2021

May 17, 2021

SELL
$9.38 - $13.63 $1,482 - $2,153
-158 Reduced 2.55%
6,045 $59,000
Q3 2020

Nov 13, 2020

SELL
$9.5 - $11.14 $14,041 - $16,464
-1,478 Reduced 19.24%
6,203 $62,000
Q2 2020

Aug 14, 2020

BUY
$7.01 - $13.24 $679 - $1,284
97 Added 1.28%
7,681 $80,000
Q1 2020

May 14, 2020

SELL
$6.28 - $14.57 $8,547 - $19,829
-1,361 Reduced 15.22%
7,584 $64,000
Q4 2019

Feb 13, 2020

BUY
$6.5 - $10.73 $7,618 - $12,575
1,172 Added 15.08%
8,945 $78,000
Q3 2019

Nov 13, 2019

SELL
$8.75 - $12.85 $69,466 - $102,016
-7,939 Reduced 50.53%
7,773 $84,000
Q2 2019

Aug 14, 2019

BUY
$12.3 - $35.76 $12,976 - $37,726
1,055 Added 7.2%
15,712 $200,000
Q4 2018

Feb 15, 2019

BUY
$20.07 - $46.7 $93,847 - $218,369
4,676 Added 46.85%
14,657 $299,000
Q3 2018

Nov 20, 2018

SELL
$41.2 - $59.85 $10,094 - $14,663
-245 Reduced 2.4%
9,981 $458,000
Q2 2018

Aug 10, 2018

SELL
$48.3 - $68.25 $25,019 - $35,353
-518 Reduced 4.82%
10,226 $605,000
Q1 2018

May 17, 2018

SELL
$59.7 - $99.25 $116,056 - $192,942
-1,944 Reduced 15.32%
10,744 $731,000
Q4 2017

Feb 13, 2018

BUY
$93.85 - $132.45 $1.19 Million - $1.68 Million
12,688
12,688 $1.26 Million

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $118M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.